ADNI Depression Study

Through dynamic partnerships with the Alzheimer’s Disease Neuroimaging Initiative (ADNI-II) and industry sponsorship, the ADNI-D study is well positioned to successfully address the impact of reduced cerebral blood flow (hypoperfusion), cortical atrophy, and amyloid deposition on cognitive impairment and accelerated cognitive decline in Late Life Depression (LLD) in the context of previously documented relationships between cognitive impairment and subcortical white matter abnormalities and genetic risk factors. ADNI-D is focused on establishing improved diagnostic approaches and targeted treatment trials aimed at LLD and cognitive impairment (CI) associated with LLD, ultimately leading to improved health outcomes and reduced healthcare costs.


  • To clarify neurobiological substrates of cognitive dysfunction in LLD.
  • To clarify the impact of LLD on rate of cognitive decline over 2.5 years.
  • Use biomarkers data employed in ADNI-2 and the NIA AD Genetics Consortium to determine the genotypes needed for the genome wide association study (GWAS) for pathways and candidate gene studies that investigators may wish to pursue in future studies. Data from participants will be entered into the NIH Genome-Wide database and made available to the scientific community.

Study Design

This is a non-randomized non-treatment study. One hundred and twenty (120) subjects who meet criteria for Major Depression or LLD will be enrolled for a period of 30 months. Data from an additional 300 non-depressed subjects will be used from the previous ADNI studies for comparison. Depression history, symptom severity and health information will be collected at the initial psychiatric visit to determine eligibility. A 3T MRI and18F-AV-45 amyloid imaging will be conducted at the ADNI site for the initial clinical visit. Collection of plasma and serum for biomarkers, clinical assessments and cognitive assessments will be conducted at both time points. Blood samples will also be collected for genetic analysis.


Data Sharing

In order to provide the clinical data from this project to Initiative investigators, the Pharmaceutical Industry and the public, the entire clinical database (free of any identifying information such as name, address, or phone number) will be placed on a public web site, which will be appropriately linked to the imaging database at LONI. The database will be frequently updated, and all cleaned clinical data acquired by the ADNI-CC will be provided in real-time.

Login to access Data >